Teva Pharmaceutical Industries Limited
NYSE:TEVADrug Manufacturers - Specialty & Generic
-$1.09 today
- Market cap
- $49.28B
- Beta
- 0.85
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.36
Volume 8.86M
Average 6.22M
TEVA Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Teva Pharmaceutical Industries LimitedNYSE: TEVA
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin widens to 52.0%
Gross margin was 52.0% in Q2 FY2026, up 1.6 pp from a year earlier. On a trailing-twelve-month basis it was 52.5%, up 2.9 pp year over year. Over 3 fiscal years it widened by 5.1 pp.
Context
- Gross margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 51.8%
- Year-over-year change
- +3.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.8% | +3.1pp |
| FY2024 | 2024-12-31 | 48.7% | +0.5pp |
| FY2023 | 2023-12-31 | 48.2% | +1.5pp |
| FY2022 | 2022-12-31 | 46.7% | -1.1pp |
| FY2021 | 2021-12-31 | 47.8% | — |
Gross Margin vs competitors
How TEVA compares with its peers on the latest reported figures
- TEVA's LTM Jun 2026 gross margin of 52.5% is the 2nd highest of the 5 companies compared; the peer median is 44.4%.
- Its year-over-year change of +2.9 pp is the highest of 5, against a peer median of -0.5 pp.
- Over three fiscal years its change of +5.1 pp compares with a peer median of -1.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 61.4% | +0.8 pp | +37.0 pp | |
| LTM Jun 2026 | 52.5% | +2.9 pp | +5.1 pp | |
| LTM Sep 2026 | 49.5% | -7.0 pp | -3.9 pp | |
| LTM Jun 2026 | 39.3% | +1.7 pp | +1.9 pp | |
| LTM Jun 2026 | 34.8% | -1.8 pp | -4.9 pp | |
| Peer median (excluding TEVA) | 44.4% | -0.5 pp | -1.0 pp | |
Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15.88B | 14.93B | 15.85B | 16.54B | 17.26B |
| Cost of Revenue | 8.28B | 7.95B | 8.2B | 8.48B | 8.32B |
| Gross Profit | 7.59B | 6.97B | 7.65B | 8.06B | 8.94B |
| Gross Margin | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| Research & Development | 1.09B | 838M | 953M | 1.06B | 1.01B |
| Selling, General & Admin | 3.53B | 3.45B | 3.5B | 3.7B | 3.97B |
| Operating Expenses | 5.88B | 9.17B | 7.21B | 8.37B | 6.78B |
| Depreciation & Amortization | 1.33B | 1.31B | 1.15B | 1.06B | 1B |
| EBITDA | 4.41B | (925M) | 1.56B | 4.43B | 3.14B |
| EBITDA Margin | 27.8% | -6.2% | 9.8% | 26.8% | 18.2% |
| Operating Income | 1.72B | (2.2B) | 433M | (303M) | 2.16B |
| Operating Margin | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Interest Income | 0 | 0 | 68M | 0 | 0 |
| Interest Expense | 891M | 930M | 1.03B | 941M | 916M |
| Other Income / Expenses | (1.05B) | (945M) | (1.06B) | (980M) | (919M) |
| Income Before Tax | 667M | (3.14B) | (622M) | (1.28B) | 1.24B |
| Pre-Tax Margin | 4.2% | -21.1% | -3.9% | -7.8% | 7.2% |
| Income Tax Expense | 211M | (643M) | (7M) | 676M | (180M) |
| Net Income | 417M | (2.45B) | (559M) | (1.64B) | 1.41B |
| Net Margin | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
| EPS (Basic) | 0.38 | (2.20) | (0.50) | (1.45) | 1.23 |
| EPS (Diluted) | 0.38 | (2.20) | (0.50) | (1.45) | 1.20 |
| Weighted Avg Shares | 1.1B | 1.11B | 1.12B | 1.13B | 1.15B |
| Weighted Avg Shares (Diluted) | 1.11B | 1.11B | 1.12B | 1.13B | 1.17B |
Teva Pharmaceutical Industries Limited
NYSE:TEVA
Intrinsic Alpha fair value
Locked
Current Price
$42.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.